Compare GOGO & IKT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | GOGO | IKT |
|---|---|---|
| Founded | 1991 | 2008 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Telecommunications Equipment | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 288.6M | 209.3M |
| IPO Year | 2011 | 2020 |
| Metric | GOGO | IKT |
|---|---|---|
| Price | $2.53 | $1.30 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 3 | 9 |
| Target Price | ★ $8.50 | $5.55 |
| AVG Volume (30 Days) | ★ 2.9M | 515.3K |
| Earning Date | 11-06-2026 | 11-10-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 57.76 |
| EPS | ★ 0.06 | N/A |
| Revenue | ★ $910,491,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $4.11 | N/A |
| P/E Ratio | $46.42 | ★ N/A |
| Revenue Growth | ★ 104.74 | N/A |
| 52 Week Low | $1.96 | $1.29 |
| 52 Week High | $7.27 | $2.61 |
| Indicator | GOGO | IKT |
|---|---|---|
| Relative Strength Index (RSI) | 44.66 | 33.23 |
| Support Level | $2.30 | N/A |
| Resistance Level | $2.75 | $1.71 |
| Average True Range (ATR) | 0.40 | 0.12 |
| MACD | -0.06 | -0.01 |
| Stochastic Oscillator | 19.18 | 2.25 |
Gogo Inc is a broadband connectivity service for the business aviation market. It provides a customizable suite of smart cabin systems for integrated connectivity, inflight entertainment, and voice solutions. It generates two types of revenue: service revenue consists of monthly subscription and usage fees paid by aircraft owners and operators for telecommunication, data, and in-flight entertainment services, and equipment revenue consists of proceeds from the sale of ATG and narrowband satellite connectivity equipment and is recognized when control of the equipment is transferred to OEMs and dealers, which generally occurs when the equipment is shipped. Geographically, it operates in United States; and International as well.
Inhibikase Therapeutics Inc a clinical-stage pharmaceutical company developing therapeutics to modify the course of cardiopulmonary diseases, namely, Pulmonary Arterial Hypertension (PAH), in which aberrant signaling through type III receptor tyrosine kinases, including platelet derived growth factor receptors and a stem cell factor receptor, known as c-Kit, has been implicated. Its product candidate is IKT-001, a prodrug of imatinib mesylate (imatinib), for PAH which is an orphan indication. The company has developed its own portfolio of protein kinase inhibitors to treat bacterial and viral infections, including viral infections in the brain. It has one reporting segment, which is the business of developing protein kinase inhibitor therapeutics.